Lightwater Biosciences & Shoreline Biome

At its monthly breakfast meeting on November 9, 2021, Beacon members met in person and remotely, where we heard new company funding proposals as follows:

  • Lightwater Biosciences (speaking in person: CEO Soo-Young Kang & Bill McCullen of Launch Capital) offering biweekly subscriptions delivering freshly made, preservative- and irritant-free, perishable, short-use cycle, single-application, skincare products; and
  • Shoreline Biome (speaking in person: Paul Denslow, CEO & CSO, Mark Driscoll) developing and selling patent-protected assays for human microbiome testing and research.

Beacon members presented their due diligence reports on the following companies:

  • Dermal Photonics, offering a patented device for home laser self-treatments superior to those of a professional dermatologist at a fraction of the cost;
  • Embrace Prevention Care, which provides Personal Prevention Care, an integrated suite of geriatric telehealth and pharmacy services designed to prevent hospitalizations and lower costs of care for older adults with heart failure and other chronic conditions; and
  • NF2 Therapeutics, developing gene replacement therapy to prevent deafness, loss of mobility and devastating brain tumors from NF2, and a targeted antibody-drug conjugate to treat meningiomas from NF2, with both therapies eligible for the FDA’s Orphan Drug Designation.

We heard updates on Beacon’s portfolio companies.

About Angel Treaty

Dedicated to fostering due diligence sharing between angel groups.
This entry was posted in Beacon Angels Events, Beacon Events, Boston angel investing, Funding Presentations and tagged , , . Bookmark the permalink.